Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.

Literature DB >> 20011568

Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.

Abstract

Overview of the Disease ProcessIncidencePrognostic FactorsGeneral Therapy StandardsAccomplishments and Lack of Accomplishments During the YearSomatostatin AnalogsPeptide Receptor-Targeted TherapySelective Internal Radiotherapy (SIRT)CYTOTOXIC THERAPIES: TemozolomideVEGF Pathway InhibitorsmTOR InhibitorsDevelopment of BiomarkersWhat Needs to be Done (Application of the Accomplishments)Controversies and DisagreementsHistologic Classification and Staging of Neuroendocrine TumorsClinical Trial Design and End PointsFuture Directions.

Entities: Disease

Year: 2009 PMID： 20011568 PMCID： PMC2791386

Source DB: PubMed Journal: Gastrointest Cancer Res ISSN： 1934-7820

31 in total

1. Clinical and in vitro studies of imatinib in advanced carcinoid tumors.

Authors: James C Yao; Jun X Zhang; Asif Rashid; Sai-Ching J Yeung; Janio Szklaruk; Kenneth Hess; Keping Xie; Lee Ellis; James L Abbruzzese; Jaffer A Ajani
Journal: Clin Cancer Res Date: 2007-01-01 Impact factor: 12.531

2. An analysis of 8305 cases of carcinoid tumors.

Authors: I M Modlin; A Sandor
Journal: Cancer Date: 1997-02-15 Impact factor: 6.860

Review 3. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544

4. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

Authors: Andrew S Kennedy; William A Dezarn; Patrick McNeillie; Doug Coldwell; Charles Nutting; Dennis Carter; Ravi Murthy; Steven Rose; Richard R P Warner; David Liu; Holger Palmedo; Carroll Overton; Bonita Jones; Riad Salem
Journal: Am J Clin Oncol Date: 2008-06 Impact factor: 2.339

5. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.

Authors: Mark Kidd; Ignat Drozdov; Richard Joseph; Roswitha Pfragner; Michael Culler; Irv Modlin
Journal: Cancer Date: 2008-08-15 Impact factor: 6.860

6. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.

Authors: Manal M Hassan; Alexandria Phan; Donghui Li; Cecile G Dagohoy; Colleen Leary; James C Yao
Journal: Int J Cancer Date: 2008-08-15 Impact factor: 7.396

7. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.

Authors: Mark Kidd; Andrew V Schally; Roswitha Pfragner; Maximillian V Malfertheiner; Irvin M Modlin
Journal: Cancer Date: 2008-03-15 Impact factor: 6.860

8. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.

Authors: Eva-Maria Duerr; Yusuke Mizukami; Aylwin Ng; Ramnik J Xavier; Hirotoshi Kikuchi; Vikram Deshpande; Andrew L Warshaw; Jonathan Glickman; Matthew H Kulke; Daniel C Chung
Journal: Endocr Relat Cancer Date: 2008-03 Impact factor: 5.678

9. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors: James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal: J Clin Oncol Date: 2008-09-10 Impact factor: 44.544

Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.

1. Clinical and in vitro studies of imatinib in advanced carcinoid tumors.

2. An analysis of 8305 cases of carcinoid tumors.

Review 3. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

4. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

5. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.

6. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.

7. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.

8. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.

9. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

10. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study.

Review 1. Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Review 2. Neuroendocrine Tumors of the Esophagus: State of the Art in Diagnostic and Therapeutic Management.

Review 3. Multidisciplinary management of advanced lung neuroendocrine tumors.

4. Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor.

5. Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study.

6. Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors.

Review 7. Systemic treatment for lung carcinoids: from bench to bedside.